284 related articles for article (PubMed ID: 14612926)
1. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
3. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
5. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
6. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
Seidl H; Richtig E; Tilz H; Stefan M; Schmidbauer U; Asslaber M; Zatloukal K; Herlyn M; Schaider H
Hum Pathol; 2007 May; 38(5):768-80. PubMed ID: 17306330
[TBL] [Abstract][Full Text] [Related]
7. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
8. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases.
Becker B; Multhoff G; Farkas B; Wild PJ; Landthaler M; Stolz W; Vogt T
Exp Dermatol; 2004 Jan; 13(1):27-32. PubMed ID: 15009113
[TBL] [Abstract][Full Text] [Related]
9. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
11. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; London W; Cohn SL; Brodeur GM; Ikegaki N
Clin Cancer Res; 1999 Jun; 5(6):1491-6. PubMed ID: 10389937
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
13. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study.
de Giorgi V; Mavilia C; Massi D; Gozzini A; Aragona P; Tanini A; Sestini S; Paglierani M; Boddi V; Brandi ML; Lotti T
Arch Dermatol; 2009 Jan; 145(1):30-6. PubMed ID: 19153340
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
16. Melanoma metastasis is associated with enhanced expression of the syntenin gene.
Helmke BM; Polychronidis M; Benner A; Thome M; Arribas J; Deichmann M
Oncol Rep; 2004 Aug; 12(2):221-8. PubMed ID: 15254681
[TBL] [Abstract][Full Text] [Related]
17. The role of RhoC in growth and metastatic capacity of melanoma.
Boone B; Van Gele M; Lambert J; Haspeslagh M; Brochez L
J Cutan Pathol; 2009 Jun; 36(6):629-36. PubMed ID: 19222696
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
19. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
